Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback